Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.

Also called NCT03486561

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
OBS Pakistan (from the registry)
Registry
  • NCT NCT03486561
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03486561. Allocation not applicable; no masking; primary purpose treatment. Start 2018-04-01 (anticipated); primary completion 2018-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
Acronym
MIDA
Condition
Chronic Stable Angina
Intervention (Drug)
Ranolazine
Lead sponsor
OBS Pakistan (class: industry)

Record details

Record id
cardio:ct-nct03486561
Content hash
bf3b4c8f8f08380a248ed443649a3c5c358c01c4064ce2da9233f3ba51e611a1